Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$72 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-4 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.1
Industry P/E
--
EV/EBITDA
0.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-4
Face value
--
Shares outstanding
3,125,840
CFO
$-133.04 Mln
EBITDA
$-150.30 Mln
Net Profit
$-148.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Landos Biopharma (LABP)
| 526.0 | 4.3 | 296.4 | 655.9 | -42.5 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Landos Biopharma (LABP)
| -26.8 | -89.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Landos Biopharma (LABP)
|
22.9 | 71.7 | 0.0 | -24.8 | -- | -81.5 | -- | 2.1 |
| 0.1 | 3.6 | 0.3 | -95.1 | -21,828.5 | -265.1 | -- | 0.3 | |
| 25.6 | 2,212.9 | 174.9 | -190.4 | -118.4 | -54.6 | -- | 7.0 | |
| 2.1 | 6.0 | 0.1 | -6.2 | -15,087.2 | -15.2 | -- | 1.9 |
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1),... a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc. Read more
President, CEO & Director
Mr. Gregory Oakes
President, CEO & Director
Mr. Gregory Oakes
Headquarters
Blacksburg, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Landos Biopharma Inc (LABP) is $22.91 (NASDAQ) as of 23-May-2024 16:37 EDT. Landos Biopharma Inc (LABP) has given a return of -42.51% in the last 3 years.
Since, TTM earnings of Landos Biopharma Inc (LABP) is negative, P/E ratio is not available.
The P/B ratio of Landos Biopharma Inc (LABP) is 2.11 times as on 11-Jun-2024, a 46 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-1.04
|
0.71
|
|
2022
|
-0.05
|
0.05
|
|
2021
|
-0.51
|
0.25
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Landos Biopharma Inc (LABP) are Rs -- and Rs -- as of 02-Apr-2026.
Landos Biopharma Inc (LABP) has a market capitalisation of $ 72 Mln as on 11-Jun-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Landos Biopharma Inc (LABP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.